Remember this Bioasis Scientific Update from May 2015?

"As a result of the combined studies and with the benefit of the full collection of data, the biOasis Board of Directors supports moving MTfp-TZM to an IND and into clinical trials."

"Commented CEO, Rob Hutchison, “We’re very pleased with the latest results of the MTf-and MTfp-trastuzumab studies. MTfp-TZM met or exceeded our objectives with the key data confirming the enhanced activity of the fusion protein and as a result, our Board of Directors has placed a high priority on moving MTfp-TZM into the clinic. Until submissions are made to clinical regulators and to scientific publications, biOasis will not be releasing quantitative data from the studies, but may do so at an appropriate time in the future.”"

Well, since then they've entered into a Neuro-Oncology Research & Collaboration Agreement with Harvard and Brigham and Women’s Hospital Inc.

"The work will include moving the trastuzumab program forward towards human clinical trials."

"BWH represents the ideal partner for biOasis for this collaboration and over the coming months, we will working closely with Sean and his team and lay out the program pathways. This work shall expand our neuro-oncology program that has so far provided us with such confidence in the Transcend platform and our peptide carrier, MTfp.”

Last year, Bioasis suggested filing an IND for the MTfp-TZM in 2016. Feels like we could get an update on this anyday now.........

BearDownAZ